Today is the 1st day of #SickleCellAwarenessMonth So many awareness angles but let’s not forget that this is arguably the most neglected #GlobalHealth problem A baby with SCD is born every MINUTE Awareness is good but we need so much action. Who’s here for it?

What happens when a virologist develops recurrence of her breast cancer? She injects two viruses into the tumour to shrink it. This is either crazy or genius and I can not decide which. Apparently self experimentation does not require ethics review! tinyurl.com/2phe4cc4

rain 🌧️ does not stop cancer nor it stop us from getting #together VeloSano to #Cure #Cancer

I am speechless this afternoon .. Thank you 🙏 #brunswick city and #Medina county for amazing #Trike&Bike VeloSano to help us fund #ChildhoodCancer #Research Cleveland Clinic Children’s

Congratulations to Dr. Kate Eshleman for receiving the enterprise “Caregiver Philanthropy Award” 🎉

Good morning! Mile 18 is in the book - 6 miles to go ... #The24in24

Key factors increasing the chance of pregnancy were younger age at HCT, nonmalignant disease, no TBI or dose <8 Gy and RIC/NMA conditioning @BloodJournal - Hope for motherhood: pregnancy after allogeneic #BMT ashpublications.org/blood/article/…

Engraft was awarded the DENNIS CONFER INNOVATE AWARD from the NMDP. Congratulations, Engraft! | The ONE Forum 2024 youtu.be/mfr2o878Vjo?si… via YouTube

1/ This is the next chapter of a story about courageous patients and their families, of multidisciplinary teamwork, and hard-fought steps forward to effective therapy for #DIPG #DMG, a universally lethal cancer of the brain and spinal cord. 🧵nature.com/articles/s4158…

Menin inhibitor approved for relapsed or refractory ALL with (KMT2A) translocation in adult and pediatric patients 1 year and older. FDA approves revumenib for relapsed or refractory acute leukemia with a KMT2A translocation fda.gov/drugs/resource…

Leveraging Oncology Treatments for Vascular Anomalies my.clevelandclinic.org/podcasts/cance… via Cleveland Clinic

No new safety concerns were identified with daratumumab treatment in children and young adults with B-cell ALL or T-cell ALL/LL. ow.ly/C42E50UckmH #lymphoidneoplasia

Original Article: Blinatumomab in Standard-Risk B-Cell Acute Lymphoblastic Leukemia in Children (AALL1731) nej.md/49CVkc1 #ASH24 | ASH

Impressive results about Exa-Cel in TDT from Vertex Pharmaceuticals at # ASH - 54 patients - 98% (53/54) had achieved Transfusion free x12 months - the remaining patient is free of RBC Tx for at least 8 months Similar results about safety and efficacy in #SCD

BEACON study initial data Beam Global IN #AS24 - BASE editing in Hgb1/2 for #SCD :7 patients - less collection cycles - faster engraftment in ANC (17 days) and PLT (19 days) - one death - high level of hgb F (>60%) with improvement in total hemoglobin and less hemolysis

Dr. Rachel Rau presented 小暮伸弥 ALL1731 study at plenary session #ASH24 1- Blina decreased BM relapse significantly across all risk factors including ; hypodyploid , +MRD , Latino ethnicity, etc 2- no change in CNS relapse

Fred Hutch’s Mohamed Sorror presents the latest findings on a new health assessment model called CHARM, which helps health care teams predict which patients will survive transplantation. #ASH24 fredhutch.org/en/news/center…

Tom Hamilton, the radio announcer for #Indians / #Guardians games for 35 years and counting on Wednesday was selected by the Baseball Hall Fame for induction in Cooperstown this summer. His emotional reaction is priceless.

🚨PublicationAlert🚨 How I Treat Sickle Cell Disease with Gene Therapy, published online (authors.elsevier.com/a/1kKhU1UYwnGSK ) and in print in Blood Journal Many thanks to Alexis Thompson Julie Kanter Lakshmanan Krishnamurti Shalini Shenoy MD Brandon Triplett and A Abraham for their inputs 🙏

Thank you, everyone, for attending our January 2025 design session! We're thrilled to have our project picked and can't wait to see you all this summer. Special shoutout to our Engraft Olympic champions, “You down with A-P-P?”  — stellar teamwork! 🎉